Identifying Plasma Biomarkers for Early Detection of Transplant-associated Thrombotic Microangiopathy Using Proteomics and Metabolomics in Patients Undergoing Stem Cell Transplantation

What this Trial Is About

Researchers are studying plasma biomarkers to improve the early diagnosis of transplant-associated thrombotic microangiopathy TA-TMA, a serious complication after allogeneic hematopoietic stem cell transplantation allo-HSCT. This study aims to find molecules that can accurately diagnose and predict TA-TMA, especially in adults with malignant blood diseases like acute leukemia. The research will also evaluate whether current biomarkers can predict TA-TMA occurrence and patient survival. Participants will be part of a prospective study cohort enrolling patients undergoing allo-HSCT. Blood and urine samples will be collected at fixed times after transplantation to analyze markers such as SC5b-9, urine protein to creatinine ratio, lactate dehydrogenase, blood counts, and schistocytes. The study will use proteomics and metabolomics technologies to identify new plasma warning biomarkers for early TA-TMA detection and establish a clinical database and biobank for future research. During the study, participants will undergo regular laboratory tests on peripheral blood and urine samples to monitor TA-TMA-related biomarkers. Researchers will collect clinical data and biological samples continuously. The main outcomes measured are plasma biomarkers predicting TA-TMA from transplantation until onset, and one-year survival of TA-TMA patients. Secondary outcomes include mortality without relapse up to two years after transplantation. The study will monitor participants from transplantation through follow-up periods to gather comprehensive data on TA-TMA progression and outcomes.

Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy